|
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| This is huge news! Read below to understand what this really means to the company. |
|
 Hot Stock to Watch |
Company: BioCorRx Inc. (OTCQB: BICX)
|
End of Day:
Price: 0.082
Change (%): - 0.002 (2.38)
Volume: 82,725 |
 |
BioCorRx, Inc. Announces Reinstatement of Letter of Understanding to Acquire Naltrexone Implant Formula for Treating Addiction
Los Angeles, March 18, 2015 (GLOBE NEWSWIRE) - BioCorRx, Inc. (BICX), developer of the Start Fresh Program® used for the treatment of alcohol and opioid dependence, announces the reinstatement of the letter of understanding (LOU) to acquire Trinity Rx Solutions and all of its formulas. The list of formulas includes the naltrexone pellet formula that is used to make the implant for which the Company currently has exclusive use rights in the U.S. and abroad (excluding Australia and New Zealand). The LOU has been reinstated with the understanding that the parties will close on a definitive agreement by the end of the year.
In November 2013, President Obama signed the Drug Quality and Security Act, which changed the compounding laws to allow a new type of compounding pharmacy to be established. These compounding pharmacies, called “outsourcing facilities,” will fall under federal oversight presumably resulting in greater patient safety. The new law was the result of a deadly meningitis outbreak caused by a New England compounding pharmacy in 2012.
When and if the formulation is acquired from Trinity Rx Solutions, BioCorRx, Inc. intends to acquire one of these outsourcing facilities so that the Company can take control over production and supply of the naltrexone implant used in the Start Fresh Program. Currently, BioCorRx, Inc. has exclusive, perpetual rights to the implant, but does not own the formula. Ownership of the formula is expected to create better efficiencies for the Company. If additional formulas controlled by Trinity Rx Solutions are acquired, the Company plans to produce and market those formulas to treat their respective healthcare issues. These other formulas include compounds for treating health issues such as smoking addiction, chronic pain, and more.
“We are very pleased that Trinity agreed to reinstate this letter of understanding. Our interests are aligned and both sides want to make this happen. The acquisition plan was shelved last year due to a focus by the Company on expansion of the Start Fresh Program’s availability and cash flow. Owning the naltrexone implant formula and other formulas, while not paramount, is expected to bring down hard costs, streamline processing of orders, and create new revenue streams in the future by helping people with other health related problems outside of alcohol and opioid addiction,” stated COO and interim CEO Brady Granier.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
